Jefferies maintains its Buy rating on Insulet PODD and raises its price target to $24 from $21 a share as the company's next generation of pods awaits FDA approval.
Jefferies says, "Insulet closed out 2011 with 4Q sales of $47.2mn, largely in-line with expectations. The company remains in active communication with the FDA on the next gen pod, with approval expected by the end of 1Q/early 2Q. The launch of the next gen pod is anticipated at ADA in June and will have a positive impact on both revenue growth and profitability."
PODD closed at $19.88 a share yesterday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in